Nano Labs transfers from Nasdaq Capital Market to Global Market

HONG KONG - Web 3.0 infrastructure provider Nano Labs Ltd (NASDAQ:NA), a small-cap technology company with a market capitalization of $133 million, announced Tuesday it has been approved to transfer from the Nasdaq Capital Market to the Nasdaq Global Market, effective September 19, 2025.

The company’s shares will continue to trade under the ticker symbol "NA" following the uplisting.

"We are thrilled and honored to complete this uplisting. It represents the culmination of our team’s long-term efforts and serves as a valuable recognition from both investors and the market," said Jianping Kong, Chairman and Chief Executive Officer of Nano Labs.

Nano Labs describes itself as a provider of high throughput computing (HTC) chips and high-performance computing (HPC) chips, with a comprehensive flow processing unit architecture that integrates features of both technologies.

The company has positioned itself in the crypto assets space, adopting BNB as its primary reserve asset, while also holding reserves in other cryptocurrencies including BTC.

The Nasdaq Global Market has more stringent listing requirements than the Nasdaq Capital Market, including higher financial and liquidity standards.

This announcement was made in a company press release statement.

In other recent news, Nano Labs Ltd has entered into an At The Market Offering Agreement with Maxim Group LLC to sell Class A Ordinary Shares, aiming to raise up to $45 million. The company plans to use the funds for its crypto asset reserve strategy, research and development, and general corporate purposes. Nano Labs also announced a strategic equity investment in CEA Industries Inc., purchasing 495,050 shares at $10.10 each, along with warrants that could potentially double their holdings. Additionally, the company has significantly increased its BNB cryptocurrency holdings to 128,000 tokens, valued at over $108 million based on current market prices. In a separate development, Nano Labs appointed Can Yang as senior vice president of its subsidiary, Nano bit HK Limited, to lead digital currency strategic reserves initiatives. Meanwhile, AMI Pharm announced its injectable drug candidate AYP-101 has entered Phase 3 clinical trials for treating submental fat, with the trial expected to conclude by the end of 2025. These developments highlight ongoing strategic moves and advancements in both Nano Labs and AMI Pharm’s operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.